Fundraising FoxAeromics, LLC
New Haven, US · Founded 2016 · Delaware corporation · 2 known investors
Find your way into Aeromics, LLC
Sign up to see every warm intro you have to Aeromics, LLC
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aeromics, LLC team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aeromics is a clinical-stage pharmaceutical company developing AER-271, an intravenous aquaporin-4 (AQP4) inhibitor designed to prevent cerebral edema (brain swelling) following severe, acute ischemic stroke. Its approach targets molecular water channels to improve outcomes in neurological indications such as stroke, spinal cord injury, CNS surgery, and brain cancer.
Founders & leadership
Aeromics, LLC was founded in 2016 by Dr. Pelletier, Dr. Boron, Marc Pelletier, and William Boron.
Board
Investors · 2
How we know: the company's own site · Broadview Ventures's portfolio page · a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$14.1M disclosed across 4 rounds · 2014–2017
▶$9.4MraisedDec 2018 · 57 investors · BiotechnologyRule 506(b)
- Peter LongoDirector
- Jeffrey DraimeDirector
- Mark DayDirector
- Thomas ZindrickDirector
- Christine AntalikExecutive Officer
- Marc F. PelletierExecutive Officer, Director
- Offering amount
- $11.1M
- Amount sold
- $9.4M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$1.5MraisedJul 2017 · 11 investors · BiotechnologyRule 506(b)
- Walter BoronExecutive Officer, Director
- Frederick JonesDirector
- Peter LongoDirector
- Paul SchlatherDirector
- Paul McGuirkExecutive Officer
- George FarrExecutive Officer
- Jeff DraimeDirector
- John FosterDirector
- Marc F. PelletierExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.5M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedApr 2016 · 5 investors · BiotechnologyRule 506(b)
- Frederick JonesDirector
- Paul McGuirkExecutive Officer
- Peter LongoDirector
- Walter BoronExecutive Officer, Director
- George FarrExecutive Officer
- Marc F. PelletierExecutive Officer, Director
- John FosterDirector
- Offering amount
- $3M
- Amount sold
- $1.9M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedMar 2014 · 15 investors · BiotechnologyRule 506(b)
- Walter BoronExecutive Officer, Director
- Marc PelletierExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $1.3M
- Minimum investment
- $15K
- First sale
- Feb 2014
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Aeromics, LLC do?
- Aeromics is a clinical-stage pharmaceutical company developing AER-271, an intravenous aquaporin-4 (AQP4) inhibitor designed to prevent cerebral edema (brain swelling) following severe, acute ischemic stroke. Its approach targets molecular water channels to improve outcomes in neurological indications such as stroke, spinal cord injury, CNS surgery, and brain cancer.
- Who founded Aeromics, LLC?
- Aeromics, LLC was founded by Dr. Pelletier, Dr. Boron, Marc Pelletier, William Boron in 2016.
- Who are Aeromics, LLC's investors?
- Aeromics, LLC's investors include Broadview Ventures, Connecticut Innovations.
- How much funding has Aeromics, LLC raised?
- Aeromics, LLC has disclosed $14.1M raised across 4 rounds.
- Where is Aeromics, LLC headquartered?
- Aeromics, LLC is headquartered in New Haven, US.